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ABSTRACT A past history of pulmonary tuberculosis (TB) is a risk factor for long-term respiratory
impairment. Post-TB lung dysfunction often goes unrecognised, despite its relatively high prevalence and
its association with reduced quality of life. Importantly, specific host and pathogen factors causing lung
impairment remain unclear. Host immune responses probably play a dominant role in lung damage, as
excessive inflammation and elevated expression of lung matrix-degrading proteases are common during
TB. Variability in host genes that modulate these immune responses may determine the severity of lung
impairment, but this hypothesis remains largely untested. In this review, we provide an overview of the
epidemiological literature on post-TB lung impairment and link it to data on the pathogenesis of lung
injury from the perspective of dysregulated immune responses and immunogenetics.
Introduction
A third of the world’s population is infected with Mycobacterium tuberculosis (MTB), and over 9 million
new cases of tuberculosis (TB) are reported annually [1]. Treatment of drug-susceptible pulmonary TB is
highly effective, with 85% (66 million cases) of reported cases estimated to have been successfully treated
between 1995 and 2015 [1]. However, up to half of TB survivors have some form of persistent pulmonary
dysfunction despite microbiologic cure [2–5]. Pulmonary dysfunction, ranging from minor abnormalities
to severe breathlessness, can increase the risk of death from respiratory causes [6–9]. Furthermore, treated
TB patients appear to contribute substantially to the growing worldwide burden of chronic obstructive
pulmonary disease (COPD) [10–12]. These findings call for strategies to address pulmonary impairment
after TB (PIAT).
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A notable feature of lung involvement in TB is its striking heterogeneity. This is observed on formal lung
function testing in terms of the magnitude of pulmonary function, ranging from no impairment to severe
dysfunction [3, 7, 8] and the specific types of ventilatory defects [3, 11, 13]. Patients may present with
cavitation, fibrosis or nodular infiltrates, or have a mix of these pulmonary pathologies [14, 15]. This
immense variability may relate to host–pathogen interactions and the diverse immunological events that
can follow. We also hypothesise that heterogeneity in lung damage may be partially attributed to variation
in genes coding for or regulating host immune responses. Elucidating the immune pathways and genetic
risk factors for TB-associated lung injury could inform therapies that specifically target immunological
factors responsible for lung injury.
This review summarises the epidemiology of PIAT, examines TB-associated lung pathology potentially
linked to lung dysfunction, and reviews the immunological and plausible genetic correlates of lung tissue
damage in TB. We also describe several processes, such as pulmonary cavitation, fibrosis and
bronchiectasis, which probably contribute collectively to lung remodelling in TB and PIAT. These terms
are defined in table 1.
Search strategy
For this review we identified references in PubMed that were published up to May 2017. We specifically
searched for studies describing the epidemiology of impaired lung function post-TB treatment using the
search terms “epidemiology”, “pulmonary tuberculosis”, “pulmonary function”, “obstruction AND/OR
restrictive”, “bronchiectasis”, “fibrosis”, “cavitation” and “TB treatment”. For studies on lung pathology
and mediators of inflammation in TB we used the terms “pulmonary tuberculosis”, “lung pathology”,
“immunopathology”, “matrix metalloproteinase”, “inflammatory biomarkers OR inflammation”,
“neutrophils” and “CD4 T cells”. Genetic studies were queried using the terms “pulmonary tuberculosis”,
“genetics”, “COPD” and “idiopathic pulmonary fibrosis”. Relevant articles published in English that
resulted from the searches, and references cited therein, were reviewed.
PIAT
Epidemiology
Initial studies conducted among untreated or incompletely treated TB patients highlighted that lung
disability was a relatively common outcome [16, 17]. Many studies since have reported on lung
impairment at TB treatment completion [5, 7, 8, 18], with persistence of defects several years post cure
(table 2) [2, 4, 13]. For example, a South African study observed airflow obstruction in 68% of patients
with a history of TB treated up to 16 years (mean 5.6 years) prior to assessment [13]. Although
longitudinal studies have shown improvement in pulmonary function with TB treatment, a considerable
proportion of patients have irreversible and often progressive pulmonary defects [3, 4, 7, 8, 20]. In a
prospective study of 74 hospitalised patients with newly diagnosed TB, 54% had improved lung function
with treatment and the rest had either no change or worsening pulmonary function [3]. Even in the
TABLE 1 Definitions for processes contributing to lung remodelling during pulmonary tuberculosis (TB) and pulmonary
impairment after TB
Term Definition
Pulmonary cavitation Process by which normal pulmonary tissue is obliterated, becoming gas-filled spaces or cavities in the lung.
This process initially involves caseous necrosis of lipid pneumonia lesions, producing caseous pneumonia.
During caseation, alveolar cells and septa are destroyed along with neighbouring vessels and bronchi. Cavities
form when these regions of caseous pneumonia liquefy, fragment and are released upon coughing.
Pulmonary fibrosis Results from long-term lung tissue injury that is characterised by excessive extracellular matrix deposition in
the lung. Replacement of normal lung parenchyma with collagenous tissue results in architectural changes in
the lung, such as thickening and stiffening of the lung walls.
Bronchiectasis Manifests as irreversible bronchial dilatation and thickening of the bronchial wall. Elastic and muscular
components of the bronchial wall are destroyed in bronchiectasis. Bronchial dilatation associated with
bronchiectasis in TB may be due to multiple factors, including traction from surrounding tissue fibrosis,
caseous necrosis that makes its way into the bronchi, and elevated luminal pressure due to coughing.
Bronchiectasis can also predispose to recurrent exacerbations of purulent sputum production and possibly
bacterial pneumonia in subsequent years.
Pulmonary impairment
after TB
A broad term we use in this review to refer to lung dysfunction that includes airflow obstruction, restrictive
ventilatory defects and impaired gas exchange. Pulmonary impairment after TB is probably downstream of a
wide variety of lung remodelling events, some of which are described above. Given the lung’s considerable
reserve, these structural changes may manifest as symptoms and pulmonary disability over a period of time.
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TABLE 2 Summary of epidemiological studies investigating pulmonary impairment after tuberculosis (TB)
First author [ref.] Type of study Setting Sample size n Exposure Outcome Association/finding Major limitation
AKKARA [18] Cross-sectional India 257 Treated TB
(2 weeks
post-treatment
completion)
Airflow obstruction
measured by FEV1 and FVC
Airflow obstruction in 86.8%
of patients
Lung impairment before TB
treatment initiation was not
measured to relate to lung
impairment after treatment
completion and determine
causality.
Long-term lung disability
was not assessed.#
WILLCOX [13] Cross-sectional South Africa 71 History of TB
(up to age
16 years)
Airflow obstruction defined
as RV >120% pred and/or
FEV1/FVC ratio <70% pred
with TLC >80% of pred
Obstruction in 68% of patients
Obstruction with some
restriction in 20%
Non-obstructive decrease in
lung volume in 17%
Lung impairment before TB
treatment initiation was not
measured to relate to lung
impairment after treatment
completion and determine
causality.
Lung function was
evaluated only in patients
who could be traced after
several years of attending a
TB clinic. Selection of
patients in this way may
have contributed to survivor
bias and underestimated
lung dysfunction.
MANJI [19] Cross-sectional Tanzania 501 Treated TB
(20 weeks of
anti-TB therapy)
Airflow defects measured by
FEV1 and FVC
Lung impairment in 74% of
patients
Obstruction in 42%
Restriction in 13%
Mixed pattern in 19%
Lung impairment before TB
treatment initiation was not
measured to relate to lung
impairment after treatment
completion and determine
causality.
Long-term lung disability
was not assessed.#
HNIZDO [2] Retrospective South Africa 27660 History of 1, 2 or
⩾3 episodes of
TB
Airflow obstruction defined
as FEV1 <80%
Prevalence of airflow
obstruction after
1 episode of TB (18.4%),
2 episodes of TB (27.1%) and
⩾3 episodes of TB (35.2%)
Lung impairment is greatest
in the first 6 months following
TB diagnosis and stabilises
6 months post-TB treatment
completion
Only male mine workers
were assessed.
Continued
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TABLE 2 Continued
First author [ref.] Type of study Setting Sample size n Exposure Outcome Association/finding Major limitation
ROSS [4] Matched
retrospective
South Africa 185 TB cases
versus 185
age-matched
controls without
history of TB
History of TB Lung function loss over time
measured by FEV1 and FVC
History of TB was associated
with an adjusted mean loss of
40.3 mL·year−1 in FEV1 (95%
CI 25.4–55.1) and
42.7 mL·year−1 in FVC (95%
CI 27–58.5) compared to
controls
Only male mine workers
were assessed.
Patients were included in
the study only if they were
still working in the mines at
follow-up, nearly 4.5 years
after baseline measures.
Several subjects had left the
mines by follow-up.
Selecting only those still
working at the mines may
have contributed to survivor
bias and underestimated
lung function.
RHEE [20] Retrospective Republic of
Korea
595 Destroyed lung
resulting from a
past history of TB
Lung function loss measured
by FEV1 and FVC
Lung impairment after TB in
76.8% of patients
Cohort consisted of
hospitalised TB patients
with destroyed lungs,
thereby limiting the
generalisability of findings
to less advanced patients.
PFTs were not standardised.
PLIT [3] Prospective cohort South Africa 74 TB treatment Lung function at the end of
TB treatment
54% of patients had an
improvement in lung function
28% of patients had
obstructed airflow
24% of patients had
restricted airflow
Only study to date that has
investigated an association
between inflammation and
lung function:
elevated C-reactive protein
correlated with decreased
FEV1 % after TB treatment
completion, independent of
smoking
Cohort consisted of
hospitalised patients with
severe TB, thereby limiting
the generalisability of
findings to less advanced
patients.
Long-term lung disability
was not assessed.#
Continued
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TABLE 2 Continued
First author [ref.] Type of study Setting Sample size n Exposure Outcome Association/finding Major limitation
MAGUIRE [7] Prospective cohort Indonesia 69 TB treatment Lung function over the
course of TB treatment
Lung function improved over
the course of TB treatment;
however, 25% of the patients
had residual
moderate-to-severe TB (FEV1
<60%) at treatment
completion
Study was restricted to 69 of
115 patients who attended
all follow-up visits. Those
included were more likely to
have been cured and had
better lung function at
diagnosis compared to
those not included. This may
have underestimated the
extent of lung dysfunction
among patients with a
history of TB.
Long-term lung disability
was not assessed.#
RALPH [8] Prospective cohort Indonesia 200 TB treatment Lung function over the
course of treatment and at
treatment completion
47% of TB patients had
moderate-to-severe
pulmonary impairment at
baseline
27% of TB patients had
residual moderate-to-severe
pulmonary impairment at the
end of treatment
Long-term lung disability
was not assessed.#
PASIPANODYA [5] Case–control USA 107 active TB
cases versus 210
latent TB
controls
Treated TB
(20 weeks of
anti-TB therapy)
Airway obstruction defined
as FEV1/FVC <70% pred and
FVC >80% pred
TB patients on anti-TB
therapy have significantly
higher odds of pulmonary
impairment versus controls
with latent TB, OR 5.4 (95% CI
2.98–9.68)
Lung impairment before TB
treatment initiation was not
measured to relate to lung
impairment at treatment
completion and determine
causality.
Long-term lung disability
was not assessed.#
AMARAL [10] Cross-sectional,
population-based
study of adults
18 high and low-/
middle-income
countries
14050 History of TB Airflow defects: obstruction
defined as
post-bronchodilator FEV1/
FVC less than LLN;
restriction defined as
post-bronchodilator FVC less
than LLN
Obstruction: adjusted OR 2.51
(95% CI 1.8–3.42)
Restriction: adjusted OR 2.31
(95% CI 1.42–3.19)
Self-report of TB was used
to determine association
with airflow obstruction.
This approach may have
resulted in recall bias.
Continued
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TABLE 2 Continued
First author [ref.] Type of study Setting Sample size n Exposure Outcome Association/finding Major limitation
MENEZES [12] Cross-sectional,
population-based
5 Latin American
cities
5571 patients;
132 with a
diagnosis of TB
History of TB COPD Prevalence of COPD in 30.7%
versus 13.9% comparing
those with and without history
of TB, respectively
Smoking adjusted OR 2.33
(95% CI 1.5–3.62)
History of TB was not
confirmed by medical
records.
Lung function was not
measured
Lee [21] Retrospective Taiwan 3176 pulmonary
TB cases versus
15880 matched
controls
History of TB COPD History of TB is an
independent risk factor of
COPD (HR 2.05, 95% CI 1.77–
2.39)
Patients were considered to
have a history of TB and
COPD based on medical
treatment records.
Lung function was not
measured.
BYRNE [11] Systematic review
and meta-analysis
Multiples
countries
History of TB COPD History of TB was significantly
associated with COPD in
adults over 40 years (pooled
OR 3.05, 95% CI 2.42–3.85)
All studies included in the
meta-analysis were
cross-sectional. Thus,
precluding determination of
a temporal and causal effect
of TB on COPD.
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; RV: residual volume; TLC: total lung capacity; PFT: pulmonary function test; LLN: lower limit of normal; COPD: chronic
obstructive pulmonary disease. #: the study by HNIZDO et al. [2] demonstrated that lung impairment peaks 6 months after diagnosis, but improves 6 months post-treatment completion
before stabilising to become chronic. These studies determined lung function at treatment completion, thus their findings may not represent residual lung impairment.
https://doi.org/10.1183/16000617.0077-2017
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outpatient setting, where patients are presumably healthier than those who are hospitalised, a quarter [7]
to one-third [8] of the patients had moderate-to-severe airway limitation at treatment completion. Other
groups have corroborated these findings in multiple other settings [5, 19, 22, 23]. A limitation of many of
the studies described above, however, was their small-to-moderate sample size (study-specific limitations
are described in table 2).
An increasing number of population-based studies have demonstrated that a history of TB increases risk
for airflow obstruction and COPD [10–12, 22]. A study of 14050 patients from 18 countries revealed that
a history of TB increased risk for obstructive airway disease by 2.5-fold independent of smoking and other
clinical factors [10]. Another study (n=5571) showed a higher prevalence of COPD in those with a history
of TB (30.7%) versus those without (13.9%) [12]. In a large study of 13522 adults aged ⩾40 years set in
South Korea, a history of TB and lesions on chest radiographs were associated with 4.47 increased odds of
airflow obstruction (95% CI 3.07–6.51) after adjusting for age, smoking, body mass index (BMI) and other
confounders [24]. Furthermore, a meta-analysis demonstrated that a history of treated TB was a risk factor
for COPD (pooled OR 3.05, 95% CI 2.42–3.85) independent of smoking and age [11].
Risk factors associated with PIAT have not been fully elucidated and the relationships are probably
complicated. It has been suggested that smoking, which is an established risk factor for COPD, may
contribute to PIAT [2, 3, 5]. However, some reports have found no such association [4, 7, 8]. For example,
in one study individuals with a history of TB were twice as likely to be current smokers than those in the
non-TB group; yet, greater lung dysfunction over time in the TB group was independent of smoking in a
multivariate analysis [4]. A similar lack of association between smoking and impaired lung function was
observed among patients completing TB treatment in Indonesia [7, 8]. HIV co-infection may be an
additional risk factor for lung function decline. Several studies have now shown that HIV-infected patients
are at increased risk for impaired gas exchange as well as airway obstruction [25–27]. However, data are
conflicting and sparse with respect to lung function in HIV/TB co-infected patients [2, 8]. Other risk
factors for poor lung function after TB may include comorbidities such as diabetes, as well as
environmental factors like indoor smoke from biomass fuels. Although these risks have been linked to
COPD [26, 28], they remain to be investigated in the context of post-TB lung disability.
Variability in lung function deficits
PIAT can involve airflow obstruction and/or restrictive ventilatory defects, as well as impairment in
gas exchange (figure 1) [3, 11, 13, 15, 20]. Airflow defects can be detected by spirometry, which
quantitates the flow and volume of air inhaled and exhaled [29]. Impaired gas exchange is determined by
measuring the diffusing capacity of the lung for carbon monoxide (DLCO) [30]. The American Thoracic
Society and the European Respiratory Society provide standardised guidelines on conducting and
Bronchogenic spread and
endobronchial disease
Caseous necrosis leads
to break down of cavitary
lesions, which pass through
bronchial walls
Pulmonary cavitation
Distortion of airways
Obstruction
Reduced capacity
to expel air out of
the lungs
Decrease in FEV1
Restriction
Reduced capacity
to inhale to full
potential
Decrease in FVC
and/or increase in
FEV1/FVC ratio
Airway narrowing Stiffening of lungparenchyma
Bronchovascular
distortion
Excessive inflammation Excessive fibrosis
Fibrotic bands
Pleural thickeningBronchiectasis
Destruction of elastic and
muscular components of
bronchial walls 
FIGURE 1 Mechanisms and radiographic features associated with airflow obstruction and restrictive
ventilatory defects in patients with a history of tuberculosis. FEV1: forced expiratory volume in 1 s; FVC: forced
vital capacity.
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interpreting these tests [30–32]. Airflow obstruction is associated with decreased capacity to completely
expel air out of the lungs and is probably due to inflammation-induced narrowing of airways. In contrast,
restriction is probably linked to the reduced ability to inhale fully resulting from extensive fibrosis and
stiffening of the lung parenchyma. Lung manifestations of pneumonia are mediated, in part, by immune
mechanisms [14, 33], and so heterogeneity in pulmonary deficits in TB may be linked to variability in the
host’s response to MTB.
Airflow obstruction
Symptoms associated with airflow obstruction include dyspnoea, reduced exercise capacity and chronic
bronchitis [34]. The magnitude of airway obstruction is commonly quantified by measuring the forced
expiratory volume in 1 s (FEV1) [32]. FEV1 is reported as both an absolute volume and as a percentage of
predicted normal [32], with a 100 mL decrease in FEV1 being considered clinically significant [35]. Several
studies have observed a decline in FEV1 during and after TB treatment [3, 7, 8, 11, 13, 20]. A Korean
study found a mean FEV1 decline of 38.2±8 mL·year−1 [20] in cured TB patients that was consistent with
the rate of reduction in FEV1 over time (33±2 mL·year−1) in COPD patients without TB [20]. Comparable
rates of FEV1 decline were observed in a study comparing patients with a history of TB to age-matched
controls [4]. Additionally, a study in Indonesia (n=200) found moderate-to-severe (FEV1 <60% pred)
airflow obstruction in approximately half the patients at baseline and determined only a small
improvement of 14.8% in % FEV1 with treatment [8].
Decline in FEV1 may be linked to multiple underlying pathological mechanisms (figure 1). Pulmonary
cavitation may obliterate or distort airways, leading to airflow obstruction. In a study of serial changes in
lung structure and pulmonary function, patients with cavities had significantly lower FEV1 at baseline and
at 1 month post-TB treatment initiation compared to patients without cavities [15]. Additionally,
bronchogenic spread is a hallmark of pulmonary TB, where caseous material released during cavitary
disintegration passes through the bronchial walls [14, 36–38]. Furthermore, destruction of elastic and
muscular components of the bronchial walls resulting in bronchiectasis, which is associated with airflow
obstruction [39], was detected more frequently in patients with cavities (64%) than those without (11%) [15].
Bronchiectasis is a permanent distortion of airways that predisposes to lifelong morbidity with recurrent
episodes of purulent sputum production, haemoptysis and sometimes progression to pneumonia [40].
Bronchiectasis as a sequela of pulmonary TB has been long recognised [41] and can persist or worsen
despite TB treatment completion [42]. Post mortem autopsy studies of TB patients found bronchiectasis in
19–65% of those examined [43, 44]. It is alarming to note that in one study, conducted more recently,
86% patients had cylindrical bronchiectasis 6 months post-TB treatment on chest computed tomography
(CT) [45]. Consistently, a systematic review reported the prevalence of bronchiectasis post-TB to be
35–86% in the five CT studies they assessed [46]. Furthermore, a population-based study of >10000 adults
in China revealed that having a history of TB increased the odds of having a diagnosis of bronchiectasis
three-fold compared to those without previous TB (OR 3.07, 95% CI 1.89–4.98) [47]. However, our
understanding of the mechanisms that drive such structural changes and associated airflow obstruction
following TB are poor.
Restrictive ventilatory defects
Patients also suffer from restricted airflow [3, 13, 18, 19], where symptoms commonly include chest pain,
cough and shortness of breath. Restriction is defined either as a decrease in forced vital capacity and/or an
increase in the FEV1/forced vital capacity ratio [32]. In one study, restriction was detected at baseline and
at the end of TB treatment in 57% and 24% of patients, respectively; however, further longitudinal analyses
were not performed in this study [3]. Although airflow obstruction in TB has received the greatest
attention, mixed patterns of airflow obstruction/restrictive ventilatory defects was the most common form
of lung dysfunction in a review of population-based and observational studies conducted in South Africa [48].
Structural changes in the lung resulting from aberrant lung tissue repair (e.g. bronchovascular distortion,
fibrotic bands and pleural thickening) [15, 20, 49] may explain airflow restriction in TB patients.
Impaired diffusing capacity and ventilation/perfusion mismatch
There is also evidence for impaired gas exchange early in TB disease [50, 51]. Decrease in DLCO is
probably due to reduction in surface area for gas exchange following alveolitis or “lipoid pneumonia”,
which occurs during cavitation (described in the Granulomas to cavitation during TB section). Although
DLCO improves with treatment, some individuals may have permanently impaired diffusion and
ventilation/perfusion mismatch, resulting in chronic hypoxaemia [15, 52]. Long-term oxygen therapy is
known to improve outcomes in COPD patients with severe chronic hypoxaemic respiratory failure [53, 54].
Currently there is little information on the prevalence of severe hypoxaemia in TB survivors.
https://doi.org/10.1183/16000617.0077-2017 8
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Mediators of lung damage and dysfunction in TB
Targeted treatment of TB-associated lung impairment requires knowledge of the precise mechanisms of
immune pathology. A major barrier to studying TB immunopathogenesis longitudinally in humans is that
serial lung biopsies through disease progression and treatment, which could be used to determine local
immune pathways involved in tissue injury, are nearly impossible to obtain. Thus, our current
understanding of the immunological basis for lung tissue injury in TB derives largely from animal models.
Although TB in non-human primates and certain aspects of disease in other animal models are similar to
human disease [55, 56], no single model recapitulates the entire spectrum of human lung pathology [14].
Nevertheless, human studies and data from animal models provide compelling evidence for the crucial role
of the host’s immune response to MTB in lung remodelling (summarised in figure 2). Such host–pathogen
interactions may persist even after treatment completion. For example, a recent longitudinal study using
positron emission tomography and CT to evaluate local lung inflammation in pulmonary TB patients
demonstrated that many patients have enhancement and/or development of new inflammatory lesions
despite 6 months of anti-TB therapy and following 1 year of treatment completion [57]. Moreover, patients
deemed culture negative at the end of treatment were found to have MTB mRNA in respiratory fluids,
suggesting persistent bacterial transcription may fuel inflammatory reactions in the lung [57]. Although
this study did not conduct formal lung function tests, patients had signs and symptoms consistent with
lung impairment [57].
We also hypothesise that while certain immunological mechanisms may specifically drive TB-associated
airflow obstruction or restrictive ventilatory impairment, many patients could have considerable overlap.
Immune mediators and pathways that perhaps drive necrosis and cavitation during TB may also set up for
subsequent fibrosis. These immunological factors could potentially be targeted to prevent airflow
obstruction and/or restrictive ventilatory defects after TB.
IL-1β
Hypoxia:
HIF-1α
NF-κB
TNF-α TGF-β
MMP-1 MMP-8MMP-9
Granuloma Cavitation Fibrosis
Obstruction
MMP-3 MMP-12
Mycobacterium tuberculosis
Restriction
IFN-γ
IL-6
IL-8
IL-12
Necrosis
mtROS
Aberrant
tissue repair
Pulmonary impairment
IL-1β#
FIGURE 2 Immune mediators of tissue remodelling and lung function impairment in tuberculosis.
Transcription factors, cytokines and chemokines that drive expression of tissue-degrading enzymes or directly
mediate cavitation and/or fibrosis are shown in green. Matrix metalloproteinases (MMP) that promote
granuloma and cavitation are depicted in purple. HIF: hypoxia inducible factor; NF: nuclear factor; IL:
interleukin; TNF: tumour necrosis factor; TGF: transforming growth factor; IFN: interferon;
mtROS: mitochondrial reactive oxygen species. #: IL-1β regulates fibrogenesis in idiopathic pulmonary
fibrosis and may play a role in tuberculosis. Pathological processes contributing to the progression of lesions
may influence the development of airflow obstruction and restrictive ventilatory patterns of pulmonary
impairment.
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Granulomas to cavitation during TB
The host’s immune system responds to the invading mycobacterium and triggers granuloma formation
during primary infection [14, 58]. A granuloma is a highly organised structure consisting of many
immune cell types (e.g. macrophages, neutrophils, natural killer cells and T- and B-cells) that surround a
caseous necrotic core of MTB-infected alveolar macrophages [33, 58]. The granuloma is traditionally
thought to be host-protective by sequestering and preventing dissemination of MTB, but studies using the
zebrafish model for TB have demonstrated that granulomas can be conducive to MTB proliferation and
spread [59, 60]. Moreover, there appears to be substantial heterogeneity in the bacterial load, size and
inflammatory profile between granulomatous lesions within a single host based on recent non-human
primate studies [61–63]. It has been shown that a single or few granulomas that fail to control
mycobacterial proliferation can dramatically influence disease progression and clinical outcome [64].
A widely held view, based on data from animal models, is that these granulomas coalesce and breakdown
via liquefactive necrosis, leaving behind a cavity during active disease [56, 65]. However, human studies
suggest that cavities originate from lipid pneumonia during post-primary TB [14, 66]. These lipid
pneumonia lesions may develop into areas of caseous pneumonia as a result of caseous necrosis [14, 66].
During caseous necrosis, alveolar cells are destroyed, along with nearby structures such as vessels and
bronchi [14]. However, elastic fibres of the alveolar walls and vessels appear to remain intact [14, 67]. This
necrotic tissue begins to soften and fissure and is eventually coughed out [14, 67]. Gas-filled spaces
surrounded by a collagen capsule in turn replace normal lung tissue following cavitation.
Although the precise immune mechanisms underlying liquefactive or caseous necrosis are not fully
understood, robust immune responses probably play a significant role [68, 69]. Initial evidence for this
comes from Robert Koch’s observations over a century ago. He noted that when guinea pigs previously
infected with MTB are rechallenged, they develop necrotic lesions that expand in circumference at the site
of cutaneous injection [70]. The Koch Phenomenon has been described by others [71], including MOREIRA
et al. [72], where MTB-infected mice were treated with a recombinant bacillus Calmette–Guerin (BCG)
vaccine that released cytokines (e.g. tumour necrosis factor (TNF)-α) shown to reduce bacterial burden in
a pre-infection vaccine model. Paradoxically, post-infection treatment with BCG–TNF-α exacerbated lung
pathology without decreasing MTB load in these mice [72]. Furthermore, SHWARTZMAN [73] found that
rabbits previously injected with Gram-negative bacteria in the skin developed haemorrhagic necrosis at the
initial site of injection following an intravenous injection of the same bacteria 24 h later. This reaction may
be explained, in part, by T-cell mediated MTB-specific immune responses, given that depleting CD4+
T-cells in pre-immunised mice inhibited this reaction [74]. This study also highlighted an important role
for TNF-α in perpetuating necrosis [74]. Other studies have corroborated these findings [75]. In addition
to an excessive and tissue-damaging immune response directed towards viable and nonviable mycobacteria
[65, 76], dysregulation of host lipid metabolism has recently been hypothesised to influence caseous
necrosis [77]. We expand our discussion on possible immune mechanisms underlying lung pathology and
dysfunction in the sections below.
Regardless of the way granulomas and cavities form, they can have variable trajectories of resolution
through the course of disease or treatment, and may undergo abnormal repair resulting in focal or
extensive tissue fibrosis [14, 78]. Thus, it is plausible that host immune responses that drive inflammation,
cavitation and fibrosis contribute to the variable patterns of lung healing, manifesting as persistent airflow
obstruction and/or restrictive ventilatory defects. Additionally, differences in the quality and quantity of
immune effector responses underlying these processes may also contribute to variability in PIAT.
Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are a family of 25 potent proteases that can degrade extracellular
matrix components [79] and are probably central to TB-associated lung injury. MMPs can promote
different stages of lung remodelling during TB [80]. Transcriptomic analyses of lesion biopsies from TB
patients showed dramatic upregulation of tissue damaging networks that included MMP-1 and MMP-9
gene expression [81]. Furthermore, TB patients with chest radiographs showing extensive lung
involvement had 8.5-fold higher levels of MMP-1 in their bronchoalveolar lavage (BAL) versus patients
with less lung involvement [82]. Consistent with this, transgenic mice expressing human MMP-1 had
greater alveolar wall damage and matrix destruction following MTB infection versus wild-type mice [82].
A recent imaging study revealed that TB lesions in humans are severely hypoxic [83]. Reproducing
hypoxia in in vitro culture conditions resulted in upregulation of MMP-1 in MTB-infected cells via
hypoxia-inducible factor and nuclear factor (NF)-κB activation [83]. Collectively, these studies suggest an
important role for MMP-1 in lesion progression during TB that plausibly occurs upstream of lung
impairment.
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MMPs are tightly regulated at the level of transcription and proteolytic maturation, as well as by tissue
inhibitors of metalloproteinases (TIMPs) [84]. In a rabbit model for cavitary TB disease, MTB was shown
to drive an imbalance in MMP-1 and its specific inhibitor, TIMP-3, which associated with the progression
of consolidated regions in the lungs to cavities [85]. Also, dysregulation in MMPs/TIMPs was
demonstrated in the plasma [84] and respiratory fluids [82] of patients with active TB. Thus, uninhibited
MMP expression and activity may lead to tissue destruction that ultimately contributes to PIAT.
Multiple other MMPs have been implicated in perpetuating TB-associated lung injury. For example,
neutrophil-derived MMP-8 and -9 were associated with cavitary disease in TB patients [86]. In a pilot
study of advanced HIV/TB co-infected patients, rapid increase in MMP-8 levels following antiretroviral
therapy (ART) initiation was associated with impaired lung function nearly 2 years after TB treatment
completion [87]. These preliminary findings are in line with the tissue destructive role of MMP-8 [87].
MMP-3 [82] and -12 [88] may also induce lung injury during TB. Although TB treatment appears to
decrease sputum MMP-1, -3 and -8, they do return to normal levels [89]. Several other proteases such as
neutrophil-associated elastase, proteinase-3 and cathepsin G have also been linked to matrix degradation in
COPD and may participate in destroying lung tissue during TB [90]. Taken together, it is conceivable that
a complex network of MMPs and other proteases mediate TB-associated lung injury with long-term
impact on lung function.
Inflammatory cytokines
Few studies have directly investigated the relationship between inflammation and lung function in TB.
A study by PLIT et al. [3] demonstrated that elevated C-reactive protein, which is a non-specific
inflammatory marker, correlated with decreased FEV1 in TB patients after treatment completion. In clinical
trials of adjunctive corticosteroid versus standard therapy alone for TB [91–93], lung disability was generally
the same between groups; however, steroid administration increased vital capacity in one report [93]. It
should be noted that adjunctive steroid treatment in TB patients has been associated overall with a trend
towards improved clinical outcome [94–96], but its prolonged use at higher doses should be approached
with caution given the long-term cardiovascular and metabolic risks. Furthermore, corticosteroids broadly
suppress inflammation by inhibiting NF-κB signalling [97, 98], which regulates the expression of several
cytokines including interleukin (IL)-1, IL-2, IL-6, IL-8, TNF-α and interferon (IFN)-γ. Thus, preventing or
treating TB-associated lung impairment may require a more targeted approach.
TNF-α is a key regulator of host immune responses to TB with pleiotropic effects [99]. Intracellular
pathogen clearance via macrophage activation is a crucial host-protective role of TNF-α [99, 100]. This
cytokine can also promote apoptosis [101]. Apoptosis is a non-inflammatory mode of cell death that
eliminates infected cells; however, TNF-α-induced apoptosis appears suboptimal for MTB control [100].
Moreover, MTB can stimulate expression of an inhibitor of TNF-α, soluble TNF-receptor II (sTNF-RII),
and evade apoptosis [102]. Low levels of TNF-α may be problematic, as this has been shown to lead to
inefficient macrophage activation and reduced microbicidal activity [103]. With uninhibited MTB
replication, excessive inflammation and necrosis can ensue [103]. Conversely, elevated TNF-α levels may
drive necrosis through the induction of mitochondrial reactive oxygen species, despite reduced MTB
growth [103, 104]. The hyper-inflammatory nature of necrotic cell death can ultimately cause cavitation
and lung tissue damage. Of note, a higher ratio of TNF-α to sTNF-RI and -RII correlated with larger
cavity size [105]. Moreover, TNF-α is necessary for MMP-1 and -9 expression by monocyte–bronchial
epithelial cell networks [106, 107]. Taken together, TNF-α perhaps potentiates tissue destruction in
multiple ways during TB.
In addition to TNF-α, elevated IL-6, IL-8 and IL-12 levels in the BAL have been correlated with cavities,
bronchial wall thickening and fibrotic bands in active TB patients [108]. In another pulmonary TB study,
several cytokines were compared between patients classified as early or late responders based on
improvement in chest radiographs after 2 or 6 months of TB treatment, respectively [109]. Late responders
had higher levels of IL-1β, TNF-α and IFN-γ versus early responders [109], implicating these cytokines in
lung tissue injury. Notably, TNF-α levels can rapidly increase following TB treatment [110]. Given that
inflammatory cytokines levels are highly dynamic soon after TB treatment initiation [89, 111], lung
remodelling is perhaps ongoing during and after TB treatment completion.
Fibrogenic cytokines
Permanent changes in lung architecture after TB may be, in part, due to aberrant wound-healing
processes. Excessive collagen deposition and fibrotic scarring can occur through the course of TB disease
and treatment [14, 112]. TNF-α may play a role in tissue fibrosis after TB. Treatment of MTB-infected
rabbits with etanercept, a TNF-α antagonist, reduced expression of several genes involved in fibrosis and
collagen metabolism [113]. Transforming growth factor (TGF)-β is considered the principal mediator of
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fibrogenesis [114]. Activation of the TGF-β signalling pathway correlated with elevated collagen levels in
lung lesions before and during TB treatment [112]. In pleural TB patients, higher TGF-β levels in the
pleural fluid associated with greater pleural thickening before and after anti-TB therapy [49]. Additionally,
IL-1β has been linked to fibrosis in patients with idiopathic pulmonary fibrosis (IPF), which is a
progressive and fatal lung disease characterised by restrictive ventilatory defects [115]. Specifically, an
imbalance in IL-1β and its receptor antagonist (IL-1RA) was implicated in propagating a pro-fibrotic
milieu in IPF [116]. TB patients were reported to have a similar imbalance in IL-1β and IL-1RA that
correlated with enhanced cavity size [105]. Although this study did not evaluate the relationship between
IL-1β/IL-1RA imbalance and fibrosis [105], it is plausible that such dysregulation may contribute to
aberrant tissue repair in TB patients. Collectively, TNF-α, TGF-β and IL-1β mediated fibrogenesis may
contribute to restrictive ventilatory defects in patients with a history of TB and requires further
investigation.
Neutrophils and CD4 T-cells
Multiple cell types have been implicated in orchestrating the development and progression of lesions and
ultimately lung damage in TB. During primary infection, the first cell type infected with MTB is thought
to be the lung-resident alveolar macrophage [14, 117]. These cells release inflammatory cytokines and
chemokines upon activation, in turn recruiting both innate (natural killer cells, neutrophils, γ/δ T-cells and
dendritic cells) and adaptive immune cells to the site of infection [65, 118]. While these early events are
essential for containing the pathogen, dysregulation of immune responses probably drive caseation and
cavitation [58, 119]. Evaluating the contribution of each of these cell types in TB-associated lung damage
is beyond the scope of this review; however, we will discuss the role of neutrophils and CD4+ T-cells in
mediating tissue injury during TB disease.
Studies using murine models of TB have attributed a protective role for neutrophils very early in infection;
however, these cells appear to play an adverse role during chronic, poorly controlled TB disease [120–122].
For example, MTB-infected neutrophils were found to facilitate host-protective adaptive immune response
by delivering TB antigens to dendritic cells shortly after infection in mice [121]. Depletion of neutrophils
led to decreased migration of dendritic cells to lymph nodes, as well as delayed activation and reduced
proliferation of naïve TB-specific CD4 T-cells in these mice [121]. In contrast, massive infiltration and
accumulation of neutrophils in the lungs is associated with increased pathology later in disease [123–125].
Consistently, depletion of neutrophils reduced lung injury in a hyper-susceptible mouse model of TB [126].
In humans, neutrophils are perhaps the predominant cell type in the lungs that are infected with
replicating MTB during active pulmonary TB [127]. Moreover, it has been reported that cavitary lesions in
humans are primarily lined by neutrophils [86, 127]. Several different tissue-damaging pathways may be
triggered by neutrophils. In one study that examined lung biopsies, the cavity walls stained positive for
neutrophils expressing extracellular matrix destroying MMP-8 and -9 [86]. Another study demonstrated
that lung pathology resulting from neutrophilic inflammation during TB was dependent on calprotectin
(S100A8/A9) secretion by these cells [122]. S100A8/A9 may not only be a surrogate for lung
inflammation, but may also stimulate influx of destructive neutrophils to the lungs [122], along with other
chemokines such as CXCL5 [128].
There is a growing body of evidence for the induction of neutrophil extracellular traps in TB [129, 130],
which could fuel tissue damage and pulmonary dysfunction as observed in other lung diseases [131–133].
Neutrophil extracellular traps are released upon neutrophil activation and function to capture and kill
bacteria [134]. They are composed of chromatin fibres, histones and proteases such as myeloperoxidase
(MPO), capthesin G and neutrophil-associated elastase [134, 135]. Although these proteases have
antimicrobial properties, they can potentially drive severe lung pathology [136–138]. Of note, MMP-8 and
calprotectin have recently been found within neutrophil extracellular traps [86, 139]. Collectively, these
studies underscore the contribution of inflammatory neutrophils in driving lung injury.
CD4 T-cells mount protective TB-specific responses; however, these cells may perpetuate tissue damage if
their responses go unchecked [87, 140]. The association between CD4 T-cells and lung damage is evident
from studies of advanced HIV/TB co-infected patients. In one study, HIV/TB patients with CD4 counts
<150 cells·μL-1 were five times more likely to have a normal chest radiograph than HIV-negative TB
patients [141]. Moreover, ART-mediated reversal of CD4 lymphopenia in advanced HIV/TB patients is
associated with incident lung involvement, particularly in those who experience TB-immune reconstitution
inflammatory syndrome (IRIS) [142]. In a small study, TB-IRIS and robust CD4 T-cell recovery after ART
initiation were associated with lower FEV1 post-TB treatment completion [87]. Mechanistically,
TB-specific CD4 T-cells that secrete TNF-α and IFN-γ perhaps trigger multiple downstream pathways and
the activation of effectors like MMPs. These responses may converge on excessive inflammation and tissue
injury and subsequent lung disability.
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Genetic predisposition for lung injury in TB
Epidemiological and immunological studies point to remarkable heterogeneity in inflammation, lung
pathology and pulmonary function among TB patients. Although environmental factors like smoking or
exposure to silica among mineworkers [2–4, 7], differences in MTB virulence [143] or HIV co-infection
[2, 8, 144] may contribute to this heterogeneity, variation in the host genes that regulate immune response
to MTB could also be involved (figure 3). However, the literature is sparse in terms of the genetic
correlates of lung damage in TB (table 3). WANG et al. [145] investigated a polymorphic site in the MMP-1
promoter, which can consist of a single guanine nucleotide (1G) or have an insertion of a G (2G). Patients
with the MMP-1 1G variant were more likely to have advanced lung fibrosis a year after TB treatment
completion [145]. Other groups have demonstrated an association between MMP-1 1G and cavitary
disease [146] and TB that is primarily endobronchial [147]. TB patients carrying the MMP-1 1G allele also
had an increased risk for tracheobronchial stenosis following treatment [147]. The mechanism underlying
lung damage in the MMP-1 1G carriers remains unclear, as it is the MMP-1 2G allele that introduces an
Ets transcription binding site and increases MMP-1 expression [167]. In line with the MMP-1 2G variant’s
functional role, a study found that patients with the MMP-1 2G/2G genotype had a 6.5-fold increased risk
of permanent lesions following TB treatment versus patients with other genotypes at this locus [148].
However, this association was only in the presence of an additional variant in the monocyte
chemoattractant protein (MCP)-1 promoter (MCP-1 G/G). Patients harbouring both the MCP-1 G/G and
MMP-1 2G/2G genotypes had extensive fibrosis and increased prevalence of bronchiectasis at the end of
TB treatment [148]. These studies, however, did not assess lung function to relate to genotype and lung
pathology.
In contrast, studies have intensely interrogated genetic susceptibility for COPD [168]. Given the link
between history of TB and COPD, we hypothesise that immunogenetic risk factors associated with COPD
may be potential candidates for airflow obstruction after TB. For example, the MMP-1 2G variant
discussed above in combination with a single nucleotide polymorphism (SNP) in MMP-12 was associated
with accelerated lung function decline in COPD patients [150]. Polymorphisms in MMP-9 and -12, as well
as TIMP genes have been linked to COPD and rapid FEV1 decline [151–153, 169]. These variants may be
relevant in the context of TB-associated lung impairment and should be examined further.
Variants in inflammatory cytokine genes have also been implicated in COPD. A meta-analysis of 36 studies
demonstrated that the TNF-α -308A polymorphism increased risk of COPD in Asians [154]. In addition
to being associated with greater yearly decline in FEV1 and chronic bronchitis compared to those without
the variant allele, the TNF-α -308A polymorphism was linked to elevated sputum levels of TNF-α, IL-8
and MPO in COPD patients [155]. Gene variants of pro-inflammatory markers such as IL-8 [156], TGF-β
[157] and IL-6 [158] have been associated with airflow limitation in COPD. It is yet to be determined if all
or any of these common genetic variants play a role in contributing to lung dysfunction in TB.
Environmental
Smoking
Biofuels
Silica exposure
Host
Genetics modulate
immune response
Host
Immune response 
(adaptive and innate) drive
cavitation and fibrosis
TB-associated
pulmonary
impairment
Pathogen
MTB lineage/virulence
HIV infection
FIGURE 3 Conceptual model of factors that potentially contribute to lung impairment after tuberculosis (TB).
MTB: Mycobacterium tuberculosis.
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Immune mechanisms underlying fibrotic interstitial lung diseases, such as IPF, may overlap with those
driving fibrogenesis in TB. Thus, it is plausible that common genetic variants implicated in IPF have a role
in abnormal tissue repair, impaired gas exchange and restrictive ventilatory defects in TB patients.
Notably, variants in the IL-1 receptor antagonist and TNF-α genes have been associated with increased
risk of IPF [159, 160]. A SNP in IL-6 has been associated with decline in DLCO in the lungs of IPF
patients [161]. Furthermore, SNPs in the TGF-β gene were linked to decreased gas exchange in IPF [162,
163]. Moreover, multiple genome-wide association studies have implicated SNPs in mucin 5B (MUC5B)
TABLE 3 Immunogenetic studies of lung dysfunction potentially relevant to pulmonary impairment after tuberculosis (TB)
Biomarker/gene Polymorphism Implication on lung pathology/function Reference
TB
MMP-1 MMP-1 -1607G (1G) (rs1799750) Extensive fibrosis after 1 year of TB treatment
Cavitary disease
Endobronchial TB and tracheobronchial stenosis
[145–147]
MCP-1+MMP-1 MCP-1 -2518G (G/G)
(rs1024611)
MMP-1 -1607GG (2G/2G) Guanine
insertion at this locus
Permanent lesions after TB treatment
Fibrosis
Bronchiectasis
[148]
TOLLIP TOLLIP
rs5743899 rs3750920
Decreased TOLLIP mRNA expression
Increased inflammatory cytokine expression
Increased risk for TB
[149]
COPD
MMP-1+MMP-12 MMP-1 2G+MMP-12 nsSNP
(rs652438)
Increased rate of lung function decline [150]
MMP-9 MMP-9 -1562C/T Increased risk of COPD in a Korean population [151]
MMP-12 MMP-12
rs652438 and rs2276109
Severe (GOLD stage III) and very severe COPD (GOLD IV), lower FEV1 % [152]
TIMP-2 TIMP-2
+853G/A
-418G/C
Increased risk for COPD
Decreased transcription and stability of mRNA
[153]
TNF-α TNF-α -308G/A
(rs1800629)
Increased risk of COPD
Increased yearly reduction in FEV1
Chronic bronchitis
Elevated TNF-α, IL-8, and myeloperoxidase in sputum
[154,155]
IL-8 IL-8
rs4073
rs2227306
rs2227307
Significant decrease in FEV1 and FVC during follow-up of COPD patients [156]
IPF
TGF-β+TNF-α TGFβ (rs1800469)
+TNF-α (rs361525)
Additive effect on lung impairment measured as FEV1 [157]
IL-6 IL-6 -174G/C Decrease in FEV1 [158]
IL-1RA IL-1RN +2018C/T (rs419598)
Variable number tandem repeat
(VNTR)*2
rs2637988
Risk for fibrosing alveolitis and IPF
Increased susceptibility for IPF
Decreased IL-1RA mRNA levels that may predispose to IPF
[159, 160]
TNF-α TNF-α -308G/A
(rs1800629)
Fibrosing alveolitis risk [159]
IL-6 IL-6 intron 4A/G Lower carbon monoxide diffusion [161]
TGF-β TGF-β
Codon 10T/C(rs1982073)
Codon 25G/C(rs1800471)
Decreased gas exchange in IPF patients [162, 163]
MUC5B MUC5B rs35705950
rs868903
Associated with pulmonary fibrosis in genome-wide association
studies
Increased MUC5B expression
[164–166]
TOLLIP TOLLIP
rs5743890
rs111521887
rs5743894
Associated with reduced TOLLIP expression in lung tissue from
IPF patients
rs5743890 linked to mortality in IPF patients
MMP: matrix metalloproteinase; MCP: monocyte chemoattractant protein; COPD: chronic obstructive pulmonary disease; TIMP: tissue inhibitor
of metalloproteinase; TNF: tumour necrosis factor; IL: interleukin; IPF: idiopathic pulmonary fibrosis; TGF: transforming growth factor; GOLD:
Global Initiative for Chronic Obstructive Lung Disease; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity.
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and TOLLIP, which modulate innate immune responses, in IPF [164–166]. Genetic variation in TOLLIP is
particularly interesting, given its role in negatively regulating the TGF-β [170] and Toll-like receptor
signalling cascade [149]. TOLLIP deficiency leads to an increase in IL-6 and TNF-α secretion in mice and
humans [149, 171]. Furthermore, individuals who harboured the TOLLIP rs5743899 or rs3750920 SNP had
diminished TOLLIP mRNA expression, elevated levels of inflammatory cytokines and at an increased risk
for TB [149]. However, these SNPs have not been examined in the context of lung pathology in TB or PIAT.
Future directions
It is evident from epidemiological studies that pulmonary impairment is relatively common among
patients with a history of TB. Clinical trials investigating new drug regimens for TB should consider
including lung function tests to evaluate the impact of these therapies on long-term pulmonary morbidity.
Given the variety of lung function abnormalities, management of TB can potentially be pulmonary
impairment specific and could target specific underlying immunopathological mechanisms. Furthermore,
investigating the role of common variants in TB-associated lung injury may provide insight into the
immunopathogenesis of PIAT. Genome-wide association studies combined with global transcriptomic
analyses may also reveal novel biomarkers and networks of pathways associated with lung damage in TB.
Therapies that harness the host’s immune response to supplement existing anti-TB treatment regimens
have garnered interest [172]. Host-directed therapies that block inflammatory effectors and pathways
involved in lung damage are a particularly attractive way to reverse lung injury and improve pulmonary
function. However, the variability in inflammatory profiles and pulmonary outcomes between patients
should be considered when evaluating host-directed therapies, as patients may not all benefit equally from
a single treatment option. In fact, TOBIN et al. [103] demonstrated that TB-meningitis patients carrying a
leukotriene A4 hydrolase (LTA4H) gene variant associated with elevated TNF-α expression benefited the
most from dexamethasone adjunctive therapy compared to those without this polymorphism. Personalised
adjunctive host-directed therapies could improve TB treatment, where therapies against lung damage are
tailored to target specific immune pathways based on the patient’s inflammatory and immunogenetic
profile. In addition, the potential relative benefit of host-directed therapies targeting elements of the
inflammatory response early in the course of TB treatment versus anti-fibrotic therapies during TB
resolution is currently unknown. These and other research priorities are detailed in table 4.
In conclusion, there is a critical need for translational studies to illuminate the immunopathogenesis of
PIAT and inform prevention and therapeutic strategies. Genetic predisposition to pulmonary morbidity
after TB should also be evaluated for a comprehensive understanding of this important outcome.
TABLE 4 Summary of key research priorities to address pulmonary impairment after tuberculosis (TB)
Epidemiological studies
Population-based studies that determine the prevalence of: 1) lung function defects by type (airflow obstruction, restrictive ventilatory
defects, gas exchange abnormalities, V′/Q mismatch and mixed defects); and 2) lung damage by type (cavitation, fibrosis and
bronchiectasis)
Investigate risk factors (host, environmental, pathogen) associated with PIAT
Measure impact of PIAT on quality of life
Determine the prevalence of PIAT and characterise lung deficits in specific patient populations, such as those co-infected with HIV, who have
diabetes mellitus or are infected with multidrug-resistant TB
Basic/translational science
Delineate the immunopathogenesis of pulmonary cavitation, fibrosis and bronchiectasis in pulmonary TB
Determine the immunogenetic correlates of hyper-inflammation and tissue damage in pulmonary TB utilising genome-wide association
studies similar to those in IPF and COPD
Identify key biomarkers or immune pathways as targets for immunomodulation to reduce lung pathology in pulmonary TB
Clinical/translational science
Diagnosis and diagnostic tests: investigate the utility of chest radiographs, CT, PET-CT, pulse oximetry, 6-min walk test and PFTs prior and
post-TB treatment in diagnosing those at increased risk for PIAT
Prevention and treatment:
Develop effective vaccines to prevent TB and lung tissue damage post infection
Develop novel drugs and biologics for TB that not only shorten treatment duration, but also reduce lung tissue injury
Investigate the use of adjunctive host-directed therapy to treat TB and associated lung pathology
Evaluate the efficacy of the use of common COPD and anti-fibrotic medications in preventing and/or treatment of post-TB lung injury
These initiatives would be informed by studies that address the basic/translational science priorities described above
V′/Q: ventilation/perfusion; PIAT: pulmonary impairment after TB; IPF: idiopathic pulmonary fibrosis; COPD: chronic obstructive pulmonary
disease; CT: computed tomography; PET: positron emission tomography; PFT: pulmonary function test.
https://doi.org/10.1183/16000617.0077-2017 15
TUBERCULOSIS | S. RAVIMOHAN ET AL.
References
1 World Health Organization. Global Tuberculosis Report 2015. 20th edition. Geneva, WHO, 2015.
2 Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent
pulmonary tuberculosis following treatment. Thorax 2000; 55: 32–38.
3 Plit ML, Anderson R, Van Rensburg CE, et al. Influence of antimicrobial chemotherapy on spirometric
parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J 1998; 12: 351–356.
4 Ross J, Ehrlich RI, Hnizdo E, et al. Excess lung function decline in gold miners following pulmonary
tuberculosis. Thorax 2010; 65: 1010–1015.
5 Pasipanodya JG, Miller TL, Vecino M, et al. Pulmonary impairment after tuberculosis. Chest 2007; 131:
1817–1824.
6 Pasipanodya JG, McNabb SJ, Hilsenrath P, et al. Pulmonary impairment after tuberculosis and its contribution to
TB burden. BMC Public Health 2010; 10: 259.
7 Maguire GP, Anstey NM, Ardian M, et al. Pulmonary tuberculosis, impaired lung function, disability and quality
of life in a high-burden setting. Int J Tuberc Lung Dis 2009; 13: 1500–1506.
8 Ralph AP, Kenangalem E, Waramori G, et al. High morbidity during treatment and residual pulmonary
disability in pulmonary tuberculosis: under-recognised phenomena. PLoS One 2013; 8: e80302.
9 Schunemann HJ, Dorn J, Grant BJ, et al. Pulmonary function is a long-term predictor of mortality in the general
population: 29-year follow-up of the Buffalo Health Study. Chest 2000; 118: 656–664.
10 Amaral AF, Coton S, Kato B, et al. Tuberculosis associates with both airflow obstruction and low lung function:
BOLD results. Eur Respir J 2015; 46: 1104–1112.
11 Byrne AL, Marais BJ, Mitnick CD, et al. Tuberculosis and chronic respiratory disease: a systematic review. Int J
Infect Dis 2015; 32: 138–146.
12 Menezes AM, Hallal PC, Perez-Padilla R, et al. Tuberculosis and airflow obstruction: evidence from the
PLATINO study in Latin America. Eur Respir J 2007; 30: 1180–1185.
13 Willcox PA, Ferguson AD. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir
Med 1989; 83: 195–198.
14 Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb)
2011; 91: 497–509.
15 Long R, Maycher B, Dhar A, et al. Pulmonary tuberculosis treated with directly observed therapy: serial changes
in lung structure and function. Chest 1998; 113: 933–943.
16 Gaensler EA, Lindgren I Chronic bronchitis as an etiologic factor in obstructive emphysema; preliminary report.
Am Rev Respir Dis 1959; 80: 185–193.
17 Birath G, Caro J, Malmberg R, et al. Airways obstruction in pulmonary tuberculosis. Scand J Respir Dis 1966; 47:
27–36.
18 Akkara SA, Shah AD, Adalja M, et al. Pulmonary tuberculosis: the day after. Int J Tuberc Lung Dis 2013; 17:
810–813.
19 Manji M, Shayo G, Mamuya S, et al. Lung functions among patients with pulmonary tuberculosis in Dar es
Salaam – a cross-sectional study. BMC Pulm Med 2016; 16: 58.
20 Rhee CK, Yoo KH, Lee JH, et al. Clinical characteristics of patients with tuberculosis-destroyed lung. Int J Tuberc
Lung Dis 2013; 17: 67–75.
21 Lee CH, Lee MC, Lin HH, et al. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important
risk factors for chronic obstructive pulmonary disease. PLoS One 2012; 7: e37978.
22 de la Mora IL, Martinez-Oceguera D, Laniado-Laborin R. Chronic airway obstruction after successful treatment
of tuberculosis and its impact on quality of life. Int J Tuberc Lung Dis 2015; 19: 808–810.
23 Pefura-Yone EW, Kengne AP, Tagne-Kamdem PE, et al. Clinical significance of low forced expiratory flow
between 25% and 75% of vital capacity following treated pulmonary tuberculosis: a cross-sectional study. BMJ
Open 2014; 4: e005361.
24 Choi CJ, Choi WS, Lee SY, et al. The definition of past tuberculosis affects the magnitude of association between
pulmonary tuberculosis and respiratory dysfunction: Korea National Health and Nutrition Examination Survey,
2008–2012. J Korean Med Sci 2017; 32: 789–795.
25 Gingo MR, George MP, Kessinger CJ, et al. Pulmonary function abnormalities in HIV-infected patients during
the current antiretroviral therapy era. Am J Respir Crit Care Med 2010; 182: 790–796.
26 van Zyl Smit RN, Pai M, Yew WW, et al. Global lung health: the colliding epidemics of tuberculosis, tobacco
smoking, HIV and COPD. Eur Respir J 2010; 35: 27–33.
27 Gingo MR, He J, Wittman C, et al. Contributors to diffusion impairment in HIV-infected persons. Eur Respir J
2014; 43: 195–203.
28 Glaser S, Kruger S, Merkel M, et al. Chronic obstructive pulmonary disease and diabetes mellitus: a systematic
review of the literature. Respiration 2015; 89: 253–264.
29 Crapo RO. Pulmonary-function testing. N Engl J Med 1994; 331: 25–30.
30 Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide
uptake in the lung. Eur Respir J 2005; 26: 720–735.
31 Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338.
32 Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:
948–968.
33 Dorhoi A, Kaufmann SH. Pathology and immune reactivity: understanding multidimensionality in pulmonary
tuberculosis. Semin Immunopathol 2016; 38: 153–166.
34 Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532–555.
35 Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to
biomarkers. Eur Respir J 2008; 31: 416–469.
36 Hatipoglu ON, Osma E, Manisali M, et al. High resolution computed tomographic findings in pulmonary
tuberculosis. Thorax 1996; 51: 397–402.
37 Murata K, Itoh H, Todo G, et al. Centrilobular lesions of the lung: demonstration by high-resolution CT and
pathologic correlation. Radiology 1986; 161: 641–645.
https://doi.org/10.1183/16000617.0077-2017 16
TUBERCULOSIS | S. RAVIMOHAN ET AL.
38 Im JG, Itoh H, Shim YS, et al. Pulmonary tuberculosis: CT findings – early active disease and sequential change
with antituberculous therapy. Radiology 1993; 186: 653–660.
39 Roberts HR, Wells AU, Milne DG, et al. Airflow obstruction in bronchiectasis: correlation between computed
tomography features and pulmonary function tests. Thorax 2000; 55: 198–204.
40 Milliron B, Henry TS, Veeraraghavan S, et al. Bronchiectasis: mechanisms and imaging clues of associated
common and uncommon diseases. Radiographics 2015; 35: 1011–1030.
41 Grancher J. La dilatation des bronches chez les tuberculeux. Gazz Med de Paris 1878; 146.
42 Ko JM, Kim KJ, Park SH, et al. Bronchiectasis in active tuberculosis. Acta Radiol 2013; 54: 412–417.
43 Jones EM, Peck WM. Relationships between tuberculosis and bronchiectasis; a study of clinical and of
post-mortem material. Am Rev Tuberc 1950; 61: 387–398.
44 Salkin D. Tuberculosis as a cause of upper lobe bronchiectasis. Calif Med 1950; 73: 577–580.
45 Capone RB, Capone D, Mafort T, et al. Tomographic aspects of advanced active pulmonary tuberculosis and
evaluation of sequelae following treatment. Pulm Med 2017; 2017: 9876768.
46 Meghji J, Simpson H, Squire SB, et al. A systematic review of the prevalence and pattern of imaging defined
post-TB lung disease. PLoS One 2016; 11: e0161176.
47 Zhou YM, Wang C, Yao WZ, et al. [The prevalence and risk factors of bronchiectasis in residents aged 40 years
old and above in seven cities in China]. Zhonghua Nei Ke Za Zhi 2013; 52: 379–382.
48 Ehrlich RI, Adams S, Baatjies R, et al. Chronic airflow obstruction and respiratory symptoms following
tuberculosis: a review of South African studies. Int J Tuberc Lung Dis 2011; 15: 886–891.
49 Seiscento M, Vargas FS, Antonangelo L, et al. Transforming growth factor β-1 as a predictor of fibrosis in
tuberculous pleurisy. Respirology 2007; 12: 660–663.
50 Malmberg R. Gas exchange in pulmonary tuberculosis. II. Review of literature clinical significance and
conclusions. Scand J Respir Dis 1966; 47: 277–305.
51 Pipavath SN, Sharma SK, Sinha S, et al. High resolution CT (HRCT) in miliary tuberculosis (MTB) of the lung:
correlation with pulmonary function tests and gas exchange parameters in north Indian patients. Indian J Med
Res 2007; 126: 193–198.
52 Kim MA, Kim SH, Zo JH, et al. Right heart dysfunction in post-tuberculosis emphysema. Int J Tuberc Lung Dis
2004; 8: 1120–1126.
53 Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial.
Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93: 391–398.
54 Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and
emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681–686.
55 Flynn JL, Gideon HP, Mattila JT, et al. Immunology studies in non-human primate models of tuberculosis.
Immunol Rev 2015; 264: 60–73.
56 Helke KL, Mankowski JL, Manabe YC. Animal models of cavitation in pulmonary tuberculosis. Tuberculosis
(Edinb) 2006; 86: 337–348.
57 Malherbe ST, Shenai S, Ronacher K, et al. Persisting positron emission tomography lesion activity and
Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med 2016; 22: 1094–1100.
58 Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 2012; 12: 352–366.
59 Volkman HE, Pozos TC, Zheng J, et al. Tuberculous granuloma induction via interaction of a bacterial secreted
protein with host epithelium. Science 2010; 327: 466–469.
60 Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous
infection. Cell 2009; 136: 37–49.
61 Lin PL, Ford CB, Coleman MT, et al. Sterilization of granulomas is common in active and latent tuberculosis
despite within-host variability in bacterial killing. Nat Med 2014; 20: 75–79.
62 Gideon HP, Phuah J, Myers AJ, et al. Variability in tuberculosis granuloma T cell responses exists, but a balance
of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathog 2015; 11: e1004603.
63 Martin CJ, Cadena AM, Leung VW, et al. Digitally barcoding Mycobacterium tuberculosis reveals in vivo
infection dynamics in the macaque model of tuberculosis. MBio 2017; 8: e00312-17.
64 Coleman MT, Maiello P, Tomko J, et al. Early changes by 18fluorodeoxyglucose positron emission tomography
coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in
Cynomolgus macaques. Infect Immun 2014; 82: 2400–2404.
65 Dannenberg AM Jr, Sugimoto M. Liquefaction of caseous foci in tuberculosis. Am Rev Respir Dis 1976; 113:
257–259.
66 Hunter RL, Jagannath C, Actor JK. Pathology of postprimary tuberculosis in humans and mice: contradiction of
long-held beliefs. Tuberculosis (Edinb) 2007; 87: 267–278.
67 Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob
Agents Chemother 2003; 47: 833–836.
68 Rook GA, al Attiyah R. Cytokines and the Koch phenomenon. Tubercle 1991; 72: 13–20.
69 Dheda K, Booth H, Huggett JF, et al. Lung remodeling in pulmonary tuberculosis. J Infect Dis 2005; 192:
1201–1209.
70 Koch R. Fortsetzung uber ein Heilmittel gegen Tuberculose. Dtsch Med Wochenschr 1891; 17: 101–102.
71 Taylor JL, Turner OC, Basaraba RJ, et al. Pulmonary necrosis resulting from DNA vaccination against
tuberculosis. Infect Immun 2003; 71: 2192–2198.
72 Moreira AL, Tsenova L, Aman MH, et al. Mycobacterial antigens exacerbate disease manifestations in
Mycobacterium tuberculosis-infected mice. Infect Immun 2002; 70: 2100–2107.
73 Shwartzman G. Phenomenon of local skin reactivity to Bacillus tuberculosis: I. Skin-preparatory and reacting
potencies of tuberculin, O.T., and Bacillus tuberculosis culture filtrates. J Exp Med 1935; 61: 369–382.
74 al Attiyah R, Moreno C, Rook GA. TNFα-mediated tissue damage in mouse footpads primed with mycobacterial
preparations. Res Immunol 1992; 143: 601–610.
75 Cardona PJ, Llatjos R, Gordillo S, et al. Towards a “human-like” model of tuberculosis: intranasal inoculation of
LPS induces intragranulomatous lung necrosis in mice infected aerogenically with Mycobacterium tuberculosis.
Scand J Immunol 2001; 53: 65–71.
https://doi.org/10.1183/16000617.0077-2017 17
TUBERCULOSIS | S. RAVIMOHAN ET AL.
76 Yamamura Y, Ogawa Y, Maeda H, et al. Prevention of tuberculous cavity formation by desensitization with
tuberculin-active peptide. Am Rev Respir Dis 1974; 109: 594–601.
77 Kim MJ, Wainwright HC, Locketz M, et al. Caseation of human tuberculosis granulomas correlates with elevated
host lipid metabolism. EMBO Mol Med 2010; 2: 258–274.
78 Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and
intervention strategies. Nat Rev Microbiol 2009; 7: 845–855.
79 Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted.
Physiol Rev 2007; 87: 69–98.
80 Salgame P. MMPs in tuberculosis: granuloma creators and tissue destroyers. J Clin Invest 2011; 121: 1686–1688.
81 Subbian S, Tsenova L, Kim MJ, et al. Lesion-specific immune response in granulomas of patients with
pulmonary tuberculosis: a pilot study. PLoS One 2015; 10: e0132249.
82 Elkington P, Shiomi T, Breen R, et al. MMP-1 drives immunopathology in human tuberculosis and transgenic
mice. J Clin Invest 2011; 121: 1827–1833.
83 Belton M, Brilha S, Manavaki R, et al. Hypoxia and tissue destruction in pulmonary TB. Thorax 2016; 71:
1145–1153.
84 Arpino V, Brock M, Gill SE. The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol
2015; 44–46: 247–254.
85 Kubler A, Luna B, Larsson C, et al. Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid
cavitation and unrestrained bacterial proliferation. J Pathol 2015; 235: 431–444.
86 Ong CW, Elkington PT, Brilha S, et al. Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction
in human pulmonary tuberculosis. PLoS Pathog 2015; 11: e1004917.
87 Ravimohan S, Tamuhla N, Kung SJ, et al. Matrix metalloproteinases in tuberculosis-immune reconstitution
inflammatory syndrome and impaired lung function among advanced HIV/TB co-infected patients initiating
antiretroviral therapy. EBioMedicine 2016; 3: 100–107.
88 Subbian S, Tsenova L, O’Brien P, et al. Phosphodiesterase-4 inhibition combined with isoniazid treatment of
rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol 2011; 179:
289–301.
89 Ugarte-Gil CA, Elkington P, Gilman RH, et al. Induced sputum MMP-1, -3 & -8 concentrations during
treatment of tuberculosis. PLoS One 2013; 8: e61333.
90 Owen CA. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron
Obstruct Pulmon Dis 2008; 3: 253–268.
91 Angel JH, Chu LS, Lyons HA. Corticotropin in the treatment of tuberculosis. A controlled study. Arch Intern
Med 1961; 108: 353–369.
92 Marcus H, Yoo OH, Akyol T, et al. A randomized study of the effects of corticosteroid therapy on healing of
pulmonary tuberculosis as judged by clinical, roentgenographic, and physiologic measurements. Am Rev Respir
Dis 1963; 88: 55–64.
93 Malik SK, Martin CJ. Tuberculosis, corticosteroid therapy, and pulmonary function. Am Rev Respir Dis 1969;
100: 13–18.
94 Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal
of the literature. Clin Infect Dis 1997; 25: 872–887.
95 Critchley JA, Young F, Orton L, et al. Corticosteroids for prevention of mortality in people with tuberculosis: a
systematic review and meta-analysis. Lancet Infect Dis 2013; 13: 223–237.
96 Wallis RS. Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis. Open
Forum Infect Dis 2014; 1: ofu020.
97 Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B
activity through induction of I kappa B synthesis. Science 1995; 270: 286–290.
98 Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in
mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283–286.
99 Dorhoi A, Kaufmann SH. Tumor necrosis factor alpha in mycobacterial infection. Semin Immunol 2014; 26:
203–209.
100 Ray JC, Flynn JL, Kirschner DE. Synergy between individual TNF-dependent functions determines granuloma
performance for controlling Mycobacterium tuberculosis infection. J Immunol 2009; 182: 3706–3717.
101 Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptic and necrotic forms of cell
lysis. J Immunol 1988; 141: 2629–2634.
102 Fratazzi C, Arbeit RD, Carini C, et al. Macrophage apoptosis in mycobacterial infections. J Leukoc Biol 1999; 66:
763–764.
103 Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to
mycobacterial infections. Cell 2012; 148: 434–446.
104 Roca FJ, Ramakrishnan L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial
reactive oxygen species. Cell 2013; 153: 521–534.
105 Tsao TC, Hong J, Li LF, et al. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms,
and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis.
Chest 2000; 117: 103–109.
106 Elkington PT, Green JA, Emerson JE, et al. Synergistic up-regulation of epithelial cell matrix metalloproteinase-9
secretion in tuberculosis. Am J Respir Cell Mol Biol 2007; 37: 431–437.
107 Elkington PT, Emerson JE, Lopez-Pascua LD, et al. Mycobacterium tuberculosis up-regulates matrix
metalloproteinase-1 secretion from human airway epithelial cells via a p38 MAPK switch. J Immunol 2005; 175:
5333–5340.
108 Casarini M, Ameglio F, Alemanno L, et al. Cytokine levels correlate with a radiologic score in active pulmonary
tuberculosis. Am J Respir Crit Care Med 1999; 159: 143–148.
109 Su WL, Perng WC, Huang CH, et al. Association of reduced tumor necrosis factor α, γ interferon, and
interleukin-1β (IL-1β) but increased IL-10 expression with improved chest radiography in patients with
pulmonary tuberculosis. Clin Vaccine Immunol 2010; 17: 223–231.
https://doi.org/10.1183/16000617.0077-2017 18
TUBERCULOSIS | S. RAVIMOHAN ET AL.
110 Bekker LG, Maartens G, Steyn L, et al. Selective increase in plasma tumor necrosis factor-alpha and concomitant
clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis 1998; 178: 580–584.
111 Riou C, Perez Peixoto B, Roberts L, et al. Effect of standard tuberculosis treatment on plasma cytokine levels in
patients with active pulmonary tuberculosis. PLoS One 2012; 7: e36886.
112 DiFazio RM, Mattila JT, Klein EC, et al. Active transforming growth factor-β is associated with phenotypic
changes in granulomas after drug treatment in pulmonary tuberculosis. Fibrogenesis Tissue Repair 2016; 9: 6.
113 Tsenova L, O’Brien P, Holloway J, et al. Etanercept exacerbates inflammation and pathology in a rabbit model of
active pulmonary tuberculosis. J Interferon Cytokine Res 2014; 34: 716–726.
114 Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011; 208: 1339–1350.
115 Wilson MS, Madala SK, Ramalingam TR, et al. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A
dependent. J Exp Med 2010; 207: 535–552.
116 Barlo NP, van Moorsel CH, Korthagen NM, et al. Genetic variability in the IL1RN gene and the balance between
interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis. Clin Exp Immunol 2011; 166:
346–351.
117 Russell DG, Cardona PJ, Kim MJ, et al. Foamy macrophages and the progression of the human tuberculosis
granuloma. Nat Immunol 2009; 10: 943–948.
118 Guirado E, Schlesinger LS, Kaplan G. Macrophages in tuberculosis: friend or foe. Semin Immunopathol 2013; 35:
563–583.
119 Martin CJ, Carey AF, Fortune SM. A bug’s life in the granuloma. Semin Immunopathol 2016; 38: 213–220.
120 Pedrosa J, Saunders BM, Appelberg R, et al. Neutrophils play a protective nonphagocytic role in systemic
Mycobacterium tuberculosis infection of mice. Infect Immun 2000; 68: 577–583.
121 Blomgran R, Ernst JD. Lung neutrophils facilitate activation of naive antigen-specific CD4+ T cells during
Mycobacterium tuberculosis infection. J Immunol 2011; 186: 7110–7119.
122 Gopal R, Monin L, Torres D, et al. S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology
during tuberculosis. Am J Respir Crit Care Med 2013; 188: 1137–1146.
123 Eruslanov EB, Lyadova IV, Kondratieva TK, et al. Neutrophil responses to Mycobacterium tuberculosis infection
in genetically susceptible and resistant mice. Infect Immun 2005; 73: 1744–1753.
124 Pichugin AV, Yan BS, Sloutsky A, et al. Dominant role of the sst1 locus in pathogenesis of necrotizing lung
granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am J Pathol
2009; 174: 2190–2201.
125 Repasy T, Martinez N, Lee J, et al. Bacillary replication and macrophage necrosis are determinants of neutrophil
recruitment in tuberculosis. Microbes Infect 2015; 17: 564–574.
126 Yeremeev V, Linge I, Kondratieva T, et al. Neutrophils exacerbate tuberculosis infection in genetically susceptible
mice. Tuberculosis (Edinb) 2015; 95: 447–451.
127 Eum SY, Kong JH, Hong MS, et al. Neutrophils are the predominant infected phagocytic cells in the airways of
patients with active pulmonary TB. Chest 2010; 137: 122–128.
128 Nouailles G, Dorhoi A, Koch M, et al. CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic
inflammation in tuberculosis. J Clin Invest 2014; 124: 1268–1282.
129 Repasy T, Lee J, Marino S, et al. Intracellular bacillary burden reflects a burst size for Mycobacterium tuberculosis
in vivo. PLoS Pathog 2013; 9: e1003190.
130 Ramos-Kichik V, Mondragon-Flores R, Mondragon-Castelan M, et al. Neutrophil extracellular traps are induced
by Mycobacterium tuberculosis. Tuberculosis (Edinb) 2009; 89: 29–37.
131 Narasaraju T, Yang E, Samy RP, et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute
lung injury of influenza pneumonitis. Am J Pathol 2011; 179: 199–210.
132 Grabcanovic-Musija F, Obermayer A, Stoiber W, et al. Neutrophil extracellular trap (NET) formation
characterises stable and exacerbated COPD and correlates with airflow limitation. Respir Res 2015; 16: 59.
133 Dicker AJ, Crichton ML, Pumphrey EG, et al. Neutrophil extracellular traps are associated with disease severity
and microbiota diversity in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2018; 141: 117–127.
134 Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303:
1532–1535.
135 Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol 2012;
189: 2689–2695.
136 Guyot N, Wartelle J, Malleret L, et al. Unopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe
lung damage and emphysema. Am J Pathol 2014; 184: 2197–2210.
137 Cheng OZ, Palaniyar N. NET balancing: a problem in inflammatory lung diseases. Front Immunol 2013; 4: 1.
138 Hoenderdos K, Condliffe A. The neutrophil in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol
2013; 48: 531–539.
139 Urban CF, Ermert D, Schmid M, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein
complex involved in host defense against Candida albicans. PLoS Pathog 2009; 5: e1000639.
140 Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev 2011; 24: 351–376.
141 Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, et al. Significant variation in presentation of pulmonary
tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis 2010; 14: 1295–1302.
142 Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome:
case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516–523.
143 Via LE, Weiner DM, Schimel D, et al. Differential virulence and disease progression following Mycobacterium
tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun 2013; 81: 2909–2919.
144 Walker NF, Clark SO, Oni T, et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix
metalloproteinases. Am J Respir Crit Care Med 2012; 185: 989–997.
145 Wang CH, Lin HC, Lin SM, et al. MMP-1(-1607G) polymorphism as a risk factor for fibrosis after pulmonary
tuberculosis in Taiwan. Int J Tuberc Lung Dis 2010; 14: 627–634.
146 Ninomiya S, Niimi T, Shimizu S, et al. Matrix metalloproteinase-1 polymorphism of promoter region in
sarcoidosis and tuberculosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 19–24.
147 Kuo HP, Wang YM, Wang CH, et al. Matrix metalloproteinase-1 polymorphism in Taiwanese patients with
endobronchial tuberculosis. Tuberculosis (Edinb) 2008; 88: 262–267.
https://doi.org/10.1183/16000617.0077-2017 19
TUBERCULOSIS | S. RAVIMOHAN ET AL.
148 Ganachari M, Guio H, Zhao N, et al. Host gene-encoded severe lung TB: from genes to the potential pathways.
Genes Immun 2012; 13: 605–620.
149 Shah JA, Vary JC, Chau TT, et al. Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms
are associated with susceptibility to tuberculosis. J Immunol 2012; 189: 1737–1746.
150 Joos L, He JQ, Shepherdson MB, et al. The role of matrix metalloproteinase polymorphisms in the rate of decline
in lung function. Hum Mol Genet 2002; 11: 569–576.
151 Lee SY, Kim MJ, Kang HG, et al. Polymorphisms in matrix metalloproteinase-1, -9 and -12 genes and the risk of
chronic obstructive pulmonary disease in a Korean population. Respiration 2010; 80: 133–138.
152 Haq I, Chappell S, Johnson SR, et al. Association of MMP-2 polymorphisms with severe and very severe COPD:
a case control study of MMPs-1, 9 and 12 in a European population. BMC Med Genet 2010; 11: 7.
153 Hirano K, Sakamoto T, Uchida Y, et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic
obstructive pulmonary disease. Eur Respir J 2001; 18: 748–752.
154 Zhang L, Gu H, Gu Y, et al. Association between TNF-α -308 G/A polymorphism and COPD susceptibility: a
meta-analysis update. Int J Chron Obstruct Pulmon Dis 2016; 11: 1367–1379.
155 Sapey E, Wood AM, Ahmad A, et al. Tumor necrosis factor-α rs361525 polymorphism is associated with
increased local production and downstream inflammation in chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 2010; 182: 192–199.
156 Cordoba-Lanus E, Baz-Davila R, Espinoza-Jimenez A, et al. IL-8 gene variants are associated with lung function
decline and multidimensional BODE index in COPD patients but not with disease susceptibility: a validation
study. COPD 2015; 12: 55–61.
157 Chiang CH, Chuang CH, Liu SL. Transforming growth factor-β1 and tumor necrosis factor-α are associated with
clinical severity and airflow limitation of COPD in an additive manner. Lung 2014; 192: 95–102.
158 He JQ, Foreman MG, Shumansky K, et al. Associations of IL6 polymorphisms with lung function decline and
COPD. Thorax 2009; 64: 698–704.
159 Whyte M, Hubbard R, Meliconi R, et al. Increased risk of fibrosing alveolitis associated with interleukin-1
receptor antagonist and tumor necrosis factor-α gene polymorphisms. Am J Respir Crit Care Med 2000; 162:
755–758.
160 Korthagen NM, van Moorsel CH, Kazemier KM, et al. IL1RN genetic variations and risk of IPF: a meta-analysis
and mRNA expression study. Immunogenetics 2012; 64: 371–377.
161 Pantelidis P, Fanning GC, Wells AU, et al. Analysis of tumor necrosis factor-α, lymphotoxin-α, tumor necrosis
factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir
Crit Care Med 2001; 163: 1432–1436.
162 Xaubet A, Marin-Arguedas A, Lario S, et al. Transforming growth factor-β1 gene polymorphisms are associated
with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 431–435.
163 Son JY, Kim SY, Cho SH, et al. TGF-β1 T869C polymorphism may affect susceptibility to idiopathic pulmonary
fibrosis and disease severity. Lung 2013; 191: 199–205.
164 Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis.
N Engl J Med 2011; 364: 1503–1512.
165 Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci
for pulmonary fibrosis. Nat Genet 2013; 45: 613–620.
166 Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and
mortality: a genome-wide association study. Lancet Respir Med 2013; 1: 309–317.
167 Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1
promoter creates an Ets binding site and augments transcription. Cancer Res 1998; 58: 5321–5325.
168 Marciniak SJ, Lomas DA. Genetic susceptibility. Clin Chest Med 2014; 35: 29–38.
169 Hegab AE, Sakamoto T, Uchida Y, et al. Association analysis of tissue inhibitor of metalloproteinase2 gene
polymorphisms with COPD in Egyptians. Respir Med 2005; 99: 107–110.
170 Zhu L, Wang L, Luo X, et al. Tollip, an intracellular trafficking protein, is a novel modulator of the transforming
growth factor-β signaling pathway. J Biol Chem 2012; 287: 39653–39663.
171 Didierlaurent A, Brissoni B, Velin D, et al. Tollip regulates proinflammatory responses to interleukin-1 and
lipopolysaccharide. Mol Cell Biol 2006; 26: 735–742.
172 Zumla A, Rao M, Wallis RS, et al. Host-directed therapies for infectious diseases: current status, recent progress,
and future prospects. Lancet Infect Dis 2016; 16: e47–e63.
https://doi.org/10.1183/16000617.0077-2017 20
TUBERCULOSIS | S. RAVIMOHAN ET AL.
